| 09.08 15:04 | MÄRKTE USA/Wall Street mit Geopolitik im Minus gesehen |
| 08.08 22:44 | dpa-AFX: ROUNDUP: Gilead Sciences Q2 Profit Rises, Revises Full-year Guidance |
| 08.08 22:33 | dpa-AFX: Gilead Sciences Inc. Bottom Line Rises In Q2, But Misses Estimates |
| 08.08 22:17 | dpa-AFX: *GILEAD SCIENCES Q2 EPS $1.29 VS. $0.83 YEAR AGO |
| 08.08 22:17 | dpa-AFX: *GILEAD SCIENCES Q2 NET INCOME TO CO. $1.61 BLN VS. $1.05 BLN PRIOR YEAR |
| 08.08 22:17 | dpa-AFX: *GILEAD SCIENCES Q2 REVENUES $6.95 BLN VS. $6.60 BLN LAST YEAR |
| 08.08 12:01 | dpa-AFX: Gilead Sciences Q2 24 Earnings Conference Call At 4:30 PM ET |
| 30.07 10:19 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
| 29.07 10:15 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
| 25.07 16:40 | dpa-AFX: Gilead's New Data Reinforce Biktarvy As Long-Term HIV Treatment Option; Stock Up |
| 25.07 15:22 | dpa-AFX: *GILEAD: NEW 5-YEAR DATA REINFORCE BIKTARVY AS LONG-TERM HIV TREATMENT OPTION |
| 24.07 20:48 | dpa-AFX: Gilead's Twice-yearly Injection Offers 100% Protection Against HIV In Women: Study |
| 24.07 12:08 | dpa-AFX: Gilead Sciences Reports New Efficacy, Safety Results From Lenacapavir Trial For HIV Prevention |
| 24.07 10:43 | dpa-AFX: *GILEAD SCIENCES ANNOUNCES FULL EFFICACY AND SAFETY RESULTS FROM PHASE 3 PURPOSE 1 TRIAL |
| 23.07 20:49 | dpa-AFX: Researchers Suggest That A Costly New HIV Drug By Gilead Could Cost As Little As $40 |
| 22.07 10:10 | dpa-AFX: *GILEAD AND THE ELTON JOHN AIDS FOUNDATION ANNOUNCE ADDITIONAL FIVE YEARS OF RADIAN PARTNERSHIP |
| 17.07 16:01 | dpa-AFX: Gilead Sciences Chief Medical Officer Merdad Parsey To Resign |
| 17.07 15:21 | dpa-AFX: *GILEAD SCIENCES CHIEF MEDICAL OFFICER MERDAD PARSEY TO STEP DOWN |
| 21.06 22:10 | MÄRKTE USA/Knapp behauptet am Hexensabbat |
| 21.06 18:26 | MÄRKTE USA/Wall Street stabilisiert sich |
|
|
